Sangamo BioSciences | SGMO - Ebit


Sangamo BioSciences reported $-72.22M in EBIT for its fiscal quarter ending in June of 2023.





Ebit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Amgen USD 3.96B 464M Dec/2025
Bayer EUR -399M 363M Sep/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 2.75B 1.35B Dec/2024
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
J&J USD 5.11B 2.3B Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
Merck USD 6.24B 1.32B Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Omeros USD -48.15M 7.25M Sep/2023
Pfizer USD 4.65B 71M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Tectonic Therapeutic USD -22.33M 4.03M Jun/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025